Last updated: Jun 9, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT06790602 | 2 | Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma | PD-1 -- immune checkpoint inhibitor (monoclonal antibody) |
| NCT07145450 | 1, 2 | Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC | KRAS G12V/D -- TCR-engineered T cells |
| NCT06158139 | 1 | Autologous CAR-T Cells Targeting B7-H3 in PDAC | B7-H3 -- CAR-T cell therapy |
| NCT07214298 | 1, 2 | Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma | Complement C3 -- complement inhibitor (pegcetacoplan) combined with chemotherapy |
| NCT07277413 | 1 | A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors | MTAP-deletion -- unknown mechanism targeted therapy |
| Sponsor | Recruiting trials |
|---|---|
| Fudan University | 21 |
| Zhejiang University | 13 |
| Tianjin Medical University Cancer Institute and Hospital | 12 |
| Ruijin Hospital | 11 |
| M.D. Anderson Cancer Center | 9 |
Countries/regions with the most active trial sites for pancreatic cancer. A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Dec 16, 2026 | NCT07608627 | 64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic Cancer | PSCA -- radiolabeled antibody fragment for imaging (radioconjugate) |
| Nov 1, 2026 | NCT07587827 | Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer | Neoantigens + CTLA-4 -- personalized DNA neoantigen vaccine combined with immune checkpoint blockade (anti-CTLA4 antibody) |
| Sep 30, 2026 | NCT07394205 | Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer | CLDN18.2 -- CAR-T cell therapy |
| Sep 8, 2026 | NCT07619521 | Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a, for Advanced Pancreatic Ductal Adenocarcinoma | MEK1/2 + HER2 -- MEK inhibitor + antibody-drug conjugate (ADC) |
| Jul 1, 2026 | NCT07377526 | Phase 1/2 Study TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer | TROP2-targeted CAR NK cells with IL-15 expression and TGFBR2 knockout + HIF-2α inhibition (Belzutifan) |
| Jul 2026 | NCT07153289 | CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa) | CD318 -- CAR-T cell therapy targeting CD318 |
| Jul 2026 | NCT07594067 | TCR1188-ABC Cells in KRAS-mutated Cancers | KRAS mutant peptides -- T cell receptor (TCR) engineered T cells |
| Jun 30, 2026 | NCT07627191 | GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer | GLP-1 receptor -- receptor agonist (GLP-1 RA) |
You've seen the pancreatic cancer landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.